<DOC>
	<DOC>NCT02179931</DOC>
	<brief_summary>To establish bioequivalence of flupentixol/melitracen between a new film-coated tablet formulation of 0.5 mg flupentixol/10 mg melitracen and the marketed coated tablet formulation of 0.5 mg flupentixol/10 mg melitracen (Deanxit®), administered as single doses.</brief_summary>
	<brief_title>Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)</brief_title>
	<detailed_description />
	<mesh_term>Flupenthixol</mesh_term>
	<mesh_term>Flupenthixol decanoate</mesh_term>
	<criteria>Healthy men and women ≥18 and ≤55 years of age with a body mass index (BMI) of &gt;18.5 and &lt;30 kg/m2. Women will be nonpregnant and nonlactating. Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>